The "connection" between HIV drug resistance and RNase H

Viruses

Volumn 2, Issue 7, 2010, Pages 1476-1503

  Delviks Frankenberry, Krista A ^a   Nikolenko, Galina N ^a,b   Pathak, Vinay K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Meso Scale Discovery   (United States)

Author keywords

Connection subdomain; Drug resistance; HIV; Nnrti; NRTI; RNase H

Indexed keywords

AMINO ACID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CARBOXY TERMINAL SEQUENCE; DRUG TARGETING; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PREVALENCE; PROTEIN DOMAIN; REVIEW; VIRUS MUTATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952178100     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2071476     Document Type: Review

References (114)

1. Quagliarello, V. The Acquired Immunodeficiency Syndrome: current status. Yale J. Biol. Med. 1982, 55, 443-452.
2. Gottlieb, M.S.; Schroff, R.; Schanker, H.M.; Weisman, J.D.; Fan, P.T.; Wolf, R.A.; Saxon, A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 1981, 305, 1425-1431.
3. Friedman-Kien, A.; Laubenstein, L.; Marmor, M.; Hymes, K.; Green, J.; Ragaz, A.; Gottlieb, J.; Muggia, F.; Demopoulos, R.; Weintraub, M.; Williams, D. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California. MMWR Morb. Mortal. Wkly. Rep. 1981, 30, 305-308.
4. Mitsuya, H.; Weinhold, K.J.; Furman, P.A.; St Clair, M.H.; Lehrman, S.N.; Gallo, R.C.; Bolognesi, D.; Barry, D.W.; Broder, S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7096-7100.
5. di Marzo Veronese, F.; Copeland, T.D.; DeVico, A.L.; Rahman, R.; Oroszlan, S.; Gallo, R.C.; Sarngadharan, M.G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 1986, 231, 1289-1291.
6. Lowe, D.M.; Aitken, A.; Bradley, C.; Darby, G.K.; Larder, B.A.; Powell, K.L.; Purifoy, D.J.; Tisdale, M.; Stammers, D.K. HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis. Biochemistry 1988, 27, 8884-8889.
7. Telesnitsky, A.; Goff, S.P. Reverse Transcriptase and the Generation of Retroviral DNA. In Retroviruses; Coffin, J.M.; Hughes, S.H.; Varmus, H., Eds.; Cold Spring Harbor Laboratory Press: Plainview, NY, USA, 1997; Chapter 4, pp 121-160.
8. Hirsch, M.S.; Gunthard, H.F.; Schapiro, J.M.; Brun-Vezinet, F.; Clotet, B.; Hammer, S.M.; Johnson, V.A.; Kuritzkes, D.R.; Mellors, J.W.; Pillay, D.; Yeni, P.G.; Jacobsen, D.M.; Richman, D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 2008, 47, 266-285.
9. Johnson, V.A.; Brun-Vezinet, F.; Clotet, B.; Gunthard, H.F.; Kuritzkes, D.R.; Pillay, D.; Schapiro, J.M.; Richman, D.D. Update of the Drug Resistance Mutations in HIV-1. Top. HIV Med. 2008, 16, 138-145.
10. Goody, R.S.; Muller, B.; Restle, T. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett. 1991, 291, 1-5.
11. Furman, P.A.; Fyfe, J.A.; St Clair, M.H.; Weinhold, K.; Rideout, J.L.; Freeman, G.A.; Lehrman, S.N.; Bolognesi, D.P.; Broder, S.; Mitsuya, H. et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 8333-8337.
12. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998, 38, 153-179.
13. Johnson, V.A.; Brun-Vezinet, F.; Clotet, B.; Gunthard, H.F.; Kuritzkes, D.R.; Pillay, D.; Schapiro, J.M.; Richman, D.D. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 2009, 17, 138-145.
14. Hanna, G.J.; Johnson, V.A.; Kuritzkes, D.R.; Richman, D.D.; Brown, A.J.; Savara, A.V.; Hazelwood, J.D.; D'Aquila, R.T. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. 2000, 181, 904-911.
15. Marcelin, A.G.; Delaugerre, C.; Wirden, M.; Viegas, P.; Simon, A.; Katlama, C.; Calvez, V. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol. 2004, 72, 162-165.
16. Yahi, N.; Tamalet, C.; Tourres, C.; Tivoli, N.; Ariasi, F.; Volot, F.; Gastaut, J.A.; Gallais, H.; Moreau, J.; Fantini, J. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J. Clin. Microbiol. 1999, 37, 4099-4106.
17. Perno, C.F.; Svicher, V.; Ceccherini-Silberstein, F. Novel drug resistance mutations in HIV: recognition and clinical relevance. AIDS Rev. 2006, 8, 179-190.
18. De Corte, B.L. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 2005, 48, 1689-1696.
19. Boyer, P.L.; Sarafianos, S.G.; Arnold, E.; Hughes, S.H. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 2001, 75, 4832-4842.
20. Meyer, P.R.; Matsuura, S.E.; Mian, A.M.; So, A.G.; Scott, W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 1999, 4, 35-43.
21. Meyer, P.R.; Matsuura, S.E.; So, A.G.; Scott, W.A. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13471-13476.
22. Arion, D.; Kaushik, N.; McCormick, S.; Borkow, G.; Parniak, M.A. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998, 37, 15908-15917.
23. Naeger, L.K.; Margot, N.A.; Miller, M.D. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 2002, 46, 2179-2184.
24. Smith, A.J.; Meyer, P.R.; Asthana, D.; Ashman, M.R.; Scott, W.A. Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations. Antimicrob. Agents Chemother. 2005, 49, 1761-1769.
25. Meyer, P.R.; Matsuura, S.E.; Tolun, A.A.; Pfeifer, I.; So, A.G.; Mellors, J.W.; Scott, W.A. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 2002, 46, 1540-1545.
26. Sarafianos, S.G.; Das, K.; Clark, A.D., Jr.; Ding, J.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10027-10032.
27. Krebs, R.; Immendorfer, U.; Thrall, S.H.; Wohrl, B.M.; Goody, R.S. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry 1997, 36, 10292-10300.
28. Feng, J.Y.; Anderson, K.S. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 1999, 38, 9440-9448.
29. Deval, J.; Navarro, J.M.; Selmi, B.; Courcambeck, J.; Boretto, J.; Halfon, P.; Garrido-Urbani, S.; Sire, J.; Canard, B. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J. Biol. Chem. 2004, 279, 25489-25496.
30. Acosta-Hoyos, W.A.; The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance. Viruses 2010, 2, 372-394.
31. Singh, K.; Marchand, B.; Kirby, K.A.; Michailidis, E.; Sarafianos, S.G. Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Viruses 2010, 2, 606-638.
32. Nikolenko, G.N.; Svarovskaia, E.S.; Delviks, K.A.; Pathak, V.K. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J. Virol. 2004, 78, 8761-8770.
33. Nikolenko, G.N.; Delviks-Frankenberry, K.A.; Palmer, S.; Maldarelli, F.; Fivash, M.J., Jr.; Coffin, J.M.; Pathak, V.K. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 317-322.
34. Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Boyer, P.L.; Hughes, S.H.; Coffin, J.M.; Jere, A.; Pathak, V.K. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 10943-10948.
35. Nikolenko, G.N.; Palmer, S.; Maldarelli, F.; Mellors, J.W.; Coffin, J.M.; Pathak, V.K. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 2093-2098.
36. Tisdale, M.; Schulze, T.; Larder, B.A.; Moelling, K. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J. Gen. Virol. 1991, 72 (Pt 1), 59-66.
37. Volkmann, S.; Wohrl, B.M.; Tisdale, M.; Moelling, K. Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H. J. Biol. Chem. 1993, 268, 2674-2683.
38. Wohrl, B.M.; Volkmann, S.; Moelling, K. Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo- and endonuclease activities. J. Mol. Biol. 1991, 220, 801-818.
39. Brehm, J.H.; Koontz, D.; Meteer, J.D.; Pathak, V.; Sluis-Cremer, N.; Mellors, J.W. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J. Virol. 2007, 81, 7852-7859.
40. Arts, E.J.; Le Grice, S.F. Interaction of retroviral reverse transcriptase with template-primer duplexes during replication. Prog. Nucleic Acid Res. Mol. Biol. 1998, 58, 339-393.
41. Ding, J.; Das, K.; Hsiou, Y.; Sarafianos, S.G.; Clark, A.D., Jr.; Jacobo-Molina, A.; Tantillo, C.; Hughes, S.H.; Arnold, E. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. J. Mol. Biol. 1998, 284, 1095-1111.
42. Ding, J.; Hughes, S.H.; Arnold, E. Protein-nucleic acid interactions and DNA conformation in a complex of human immunodeficiency virus type 1 reverse transcriptase with a double-stranded DNA template-primer. Biopolymers 1997, 44, 125-138.
43. Huang, H.; Chopra, R.; Verdine, G.L.; Harrison, S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282, 1669-1675.
44. Jacobo-Molina, A.; Ding, J.; Nanni, R.G.; Clark, A.D., Jr.; Lu, X.; Tantillo, C.; Williams, R.L.; Kamer, G.; Ferris, A.L.; Clark, P. et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6320-6324.
45. Sarafianos, S.G.; Das, K.; Tantillo, C.; Clark, A.D., Jr.; Ding, J.; Whitcomb, J.M.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J. 2001, 20, 1449-1461.
46. Arion, D.; Sluis-Cremer, N.; Min, K.L.; Abram, M.E.; Fletcher, R.S.; Parniak, M.A. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J. Biol. Chem. 2002, 277, 1370-1374.
47. Julias, J.G.; McWilliams, M.J.; Sarafianos, S.G.; Alvord, W.G.; Arnold, E.; Hughes, S.H. Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. J. Virol. 2003, 77, 8548-8554.
48. Julias, J.G.; McWilliams, M.J.; Sarafianos, S.G.; Arnold, E.; Hughes, S.H. Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 9515-9520.
49. McWilliams, M.J.; Julias, J.G.; Sarafianos, S.G.; Alvord, W.G.; Arnold, E.; Hughes, S.H. Combining mutations in HIV-1 reverse transcriptase with mutations in the HIV-1 polypurine tract affects RNase H cleavages involved in PPT utilization. Virology 2006, 348, 378-388.
50. Rausch, J.W.; Lener, D.; Miller, J.T.; Julias, J.G.; Hughes, S.H.; Le Grice, S.F. Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochemistry 2002, 41, 4856-4865.
51. Zhang, W.H.; Svarovskaia, E.S.; Barr, R.; Pathak, V.K. Y586F mutation in murine leukemia virus reverse transcriptase decreases fidelity of DNA synthesis in regions associated with adenine-thymine tracts. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10090-10095.
52. Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Barr, R.; Pathak, V.K. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. J. Virol. 2007, 81, 6837-6845.
53. Nikolenko, G.N.; Delviks-Frankenberry, K.A.; Boyer, P.L.; Hughes, S.H.; Coffin, J.M.; Jere, A.; Pathak, V.K. HIV-1 reverse transcriptase connection domain mutations reduce template RNA degradation and enhance NRTI excision. Antivir. Ther. 2008, 13 (Suppl. 3), A60.
54. Yap, S.H.; Sheen, C.W.; Fahey, J.; Zanin, M.; Tyssen, D.; Lima, V.D.; Wynhoven, B.; Kuiper, M.; Sluis-Cremer, N.; Harrigan, P.R.; Tachedjian, G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007, 4, e335.
55. Radzio, J.; Yap, S.H.; Tachedjian, G.; Sluis-Cremer, N. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. AIDS 2010, 24, 659-667.
56. Zelina, S.; Sheen, C.W.; Radzio, J.; Mellors, J.W.; Sluis-Cremer, N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob. Agents Chemother. 2008, 52, 157-163.
57. Brehm, J.H.; Mellors, J.W.; Sluis-Cremer, N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008, 47, 14020-14027.
58. Ehteshami, M.; Beilhartz, G.L.; Scarth, B.J.; Tchesnokov, E.P.; McCormick, S.; Wynhoven, B.; Harrigan, P.R.; Gotte, M. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J. Biol. Chem. 2008, 283, 22222-22232.
59. Boyer, P.L.; Sarafianos, S.G.; Arnold, E.; Hughes, S.H. The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 2002, 76, 3248-3256.
60. Gotte, M.; Arion, D.; Parniak, M.A.; Wainberg, M.A. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 2000, 74, 3579-3585.
61. Naeger, L.K.; Margot, N.A.; Miller, M.D. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir. Ther. 2001, 6, 115-126.
62. Miranda, L.R.; Gotte, M.; Liang, F.; Kuritzkes, D.R. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob. Agents Chemother. 2005, 49, 2648-2656.
63. von Wyl, V.; Ehteshami, M.; Symons, J.; Burgisser, P.; Nijhuis, M.; Demeter, L.M.; Yerly, S.; Boni, J.; Klimkait, T.; Schuurman, R.; Ledergerber, B.; Gotte, M.; Gunthard, H.F. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J. Infect. Dis. 2010, 201, 1054-1062.
64. Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Maldarelli, F.; Hase, S.; Takebe, Y.; Pathak, V.K. Subtype-Specific Differences in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Connection Subdomain of CRF01_AE Are Associated with Higher Levels of Resistance to 3'-Azido-3'-Deoxythymidine. J. Virol. 2009, 83, 8502-8513.
65. Kohlstaedt, L.A.; Wang, J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
66. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D. et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2, 293-302.
67. Smerdon, S.J.; Jager, J.; Wang, J.; Kohlstaedt, L.A.; Chirino, A.J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
68. Das, K.; Sarafianos, S.G.; Clark, A.D., Jr.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J. Mol. Biol. 2007, 365, 77-89.
69. Sarafianos, S.G.; Clark, A.D., Jr.; Das, K.; Tuske, S.; Birktoft, J.J.; Ilankumaran, P.; Ramesha, A.R.; Sayer, J.M.; Jerina, D.M.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 2002, 21, 6614-6624.
70. Hsiou, Y.; Ding, J.; Das, K.; Clark, A.D., Jr.; Boyer, P.L.; Lewi, P.; Janssen, P.A.; Kleim, J.P.; Rosner, M.; Hughes, S.H.; Arnold, E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 2001, 309, 437-445.
71. Maga, G.; Amacker, M.; Ruel, N.; Hubscher, U.; Spadari, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 1997, 274, 738-747.
72. Spence, R.A.; Anderson, K.S.; Johnson, K.A. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry 1996, 35, 1054-1063.
73. Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.M.; Parniak, M.A.; Hughes, S.H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 2009, 385, 693-713.
74. Domaoal, R.A.; Demeter, L.M. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int. J. Biochem. Cell. Biol. 2004, 36, 1735-1751.
75. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P.A.; Hughes, S.H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 407-415.
76. Ren, J.; Nichols, C.E.; Chamberlain, P.P.; Weaver, K.L.; Short, S.A.; Chan, J.H.; Kleim, J.P.; Stammers, D.K. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J. Med. Chem. 2007, 50, 2301-2309.
77. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D.I.; Stammers, D.K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 2001, 312, 795-805.
78. Das, K.; Ding, J.; Hsiou, Y.; Clark, A.D., Jr.; Moereels, H.; Koymans, L.; Andries, K.; Pauwels, R.; Janssen, P.A.; Boyer, P.L.; Clark, P.; Smith, R.H., Jr.; Kroeger Smith, M.B.; Michejda, C.J.; Hughes, S.H.; Arnold, E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 1996, 264, 1085-1100.
79. Hsiou, Y.; Das, K.; Ding, J.; Clark, A.D., Jr.; Kleim, J.P.; Rosner, M.; Winkler, I.; Riess, G.; Hughes, S.H.; Arnold, E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 1998, 284, 313-323.
80. Goulden, M.G.; Cammack, N.; Hopewell, P.L.; Penn, C.R.; Cameron, J.M. Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS 1996, 10, 101-102.
81. Kemp, S.D.; Shi, C.; Bloor, S.; Harrigan, P.R.; Mellors, J.W.; Larder, B.A. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J. Virol. 1998, 72, 5093-5098.
82. Radzio, J.; Sluis-Cremer, N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol. Pharmacol. 2008, 73, 601-606.
83. Gupta, S.; Fransen, S.; Paxinos, E. Infrequent occurrence of mutations in the C-terminal region of reverse transcriptase modulates susceptibility to RT inhibitors. Antivir. Ther. 2006, 11, S143.
84. Sluis-Cremer, N.; Moore, K.; Radzio, J.; Sonza, S.; Tachedjian, G. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. AIDS 2010, 24, 317-319.
85. Gupta, S.; Fransen, S.; Paxinos, E.E.; Stawiski, E.; Huang, W.; Petropoulos, C.J. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob. Agents Chemother. 2010, 54, 1973-1980.
86. Nikolenko, G.N.; Delviks-Frankenberry, K.A.; Pathak, V.K. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 2010, 84, 5238-5249.
87. Samuele, A.; Kataropoulou, A.; Viola, M.; Zanoli, S.; La Regina, G.; Piscitelli, F.; Silvestri, R.; Maga, G. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex. Antiviral Res. 2009, 81, 47-55.
88. Zanoli, S.; Gemma, S.; Butini, S.; Brindisi, M.; Joshi, B.P.; Campiani, G.; Fattorusso, C.; Persico, M.; Crespan, E.; Cancio, R.; Spadari, S.; Hubscher, U.; Maga, G. Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the primer grip region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants. Biochem. Pharmacol. 2008, 76, 156-168.
89. Radi, M.; Maga, G.; Alongi, M.; Angeli, L.; Samuele, A.; Zanoli, S.; Bellucci, L.; Tafi, A.; Casaluce, G.; Giorgi, G.; Armand-Ugon, M.; Gonzalez, E.; Este, J.A.; Baltzinger, M.; Bec, G.; Dumas, P.; Ennifar, E.; Botta, M. Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants. J. Med. Chem. 2009, 52, 840-851.
90. Tachedjian, G.; Goff, S.P. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr. Opin. Investig. Drugs 2003, 4, 966-973.
91. Mulky, A.; Sarafianos, S.G.; Jia, Y.; Arnold, E.; Kappes, J.C. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. J. Mol. Biol. 2005, 349, 673-684.
92. Mulky, A.; Vu, B.C.; Conway, J.A.; Hughes, S.H.; Kappes, J.C. Analysis of amino acids in the beta7-beta8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication. J. Mol. Biol. 2007, 365, 1368-1378.
93. Upadhyay, A.; Pandey, N.; Mishra, C.A.; Talele, T.T.; Pandey, V.N. A single deletion at position 134, 135, or 136 in the beta 7-beta 8 loop of the p51 subunit of HIV-1 RT disrupts the formation of heterodimeric enzyme. 2010, J. Cell Biochem. 109, 598-605.
94. Tachedjian, G.; Orlova, M.; Sarafianos, S.G.; Arnold, E.; Goff, S.P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7188-7193.
95. Figueiredo, A.; Zelina, S.; Sluis-Cremer, N.; Tachedjian, G. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. Curr. HIV Res. 2008, 6, 130-137.
96. Gopalakrishnan, V.; Benkovic, S. Effect of a thiobenzimidazolone derivative on DNA strand transfer catalyzed by HIV-1 reverse transcriptase. J. Biol. Chem. 1994, 269, 4110-4115.
97. Palaniappan, C.; Fay, P.J.; Bambara, R.A. Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J. Biol. Chem. 1995, 270, 4861-4869.
98. Shaw-Reid, C.A.; Feuston, B.; Munshi, V.; Getty, K.; Krueger, J.; Hazuda, D.J.; Parniak, M.A.; Miller, M.D.; Lewis, D. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry 2005, 44, 1595-1606.
99. Hang, J.Q.; Li, Y.; Yang, Y.; Cammack, N.; Mirzadegan, T.; Klumpp, K. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem. Biophys. Res. Commun. 2007, 352, 341-350.
100. Pelemans, H.; Esnouf, R.M.; Jonckheere, H.; De Clercq, E.; Balzarini, J. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. J. Biol. Chem. 1998, 273, 34234-34239.
101. Harrigan, P.R.; Salim, M.; Stammers, D.K.; Wynhoven, B.; Brumme, Z.L.; McKenna, P.; Larder, B.; Kemp, S.D. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J. Virol. 2002, 76, 6836-6840.
102. Dau, B.; Ayers, D.; Singer, J.; Harrigan, P.R.; Brown, S.; Kyriakides, T.; Cameron, D.W.; Angus, B.; Holodniy, M. Connection domain mutations in treatment-experienced patients in the OPTIMA trial. J. Acquir. Immune Defic. Syndr. 2010, 54, 160-166.
103. Hachiya, A.; Kodama, E.N.; Sarafianos, S.G.; Schuckmann, M.M.; Sakagami, Y.; Matsuoka, M.; Takiguchi, M.; Gatanaga, H.; Oka, S. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 2008, 82, 3261-3270.
104. Waters, J.M.; O'Neal, W.; White, K.L.; Wakeford, C.; Lansdon, E.B.; Harris, J.; Svarovskaia, E.S.; Miller, M.D.; Borroto-Esoda, K. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir. Ther. 2009, 14, 231-239.
105. Price, H.; Asboe, D.; Pozniak, A.; Gazzard, B.; Fearnhill, E.; Pillay, D.; Dunn, D. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir. Ther. 2010, 15, 203-211.
106. Santos, A.F.; Lengruber, R.B.; Soares, E.A.; Jere, A.; Sprinz, E.; Martinez, A.M.; Silveira, J.; Sion, F.S.; Pathak, V.K.; Soares, M.A. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One 2008, 3, e1781.
107. Cane, P.A.; Green, H.; Fearnhill, E.; Dunn, D. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 2007, 21, 447-455.
108. Roquebert, B.; Flandre, P.; Malet, I.; Wirden, M.; ait-arkoub, Z.; Boutonnet, V.; Simon, A.; Katlama, C.; Calvez, V.; Marcelin, A.G. Identification of a Mutation (A400T) in the Connection Domain of the HIV-1 Reverse Transcriptase Associated to Exposure and Resistance to NRTI. In 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, USA, 2007; Abstract #596.
109. Saeng-Aroon, S.; Tsuchiya, N.; Auwanit, W.; Ayuthaya, P.I.; Pathipvanich, P.; Sawanpanyalert, P.; Rojanawiwat, A.; Kannagi, M.; Ariyoshi, K.; Sugiura, W. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort. Antiviral Res. 2010, 87, 22-29.
110. Roquebert, B.; Wirden, M.; Simon, A.; Deval, J.; Katlama, C.; Calvez, V.; Marcelin, A.G. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. J. Med. Virol. 2007, 79, 207-211.
111. Ntemgwa, M.; Wainberg, M.A.; Oliveira, M.; Moisi, D.; Lalonde, R.; Micheli, V.; Brenner, B.G. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob. Agents Chemother. 2007, 51, 3861-3869.
112. Hachiya, A.; Shimane, K.; Sarafianos, S.G.; Kodama, E.N.; Sakagami, Y.; Negishi, F.; Koizumi, H.; Gatanaga, H.; Matsuoka, M.; Takiguchi, M.; Oka, S. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antiviral Res. 2009, 82, 115-121.
113. Soares, E.A.; Makamche, M.F.; Siqueira, J.D.; Lumngwena, E.; Mbuagbaw, J.; Kaptue, L.; Asonganyi, T.; Seuanez, H.N.; Soares, M.A.; Alemnji, G. Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naive Cameroonian subjects with advanced disease. J. Clin. Virol. 2010, 48, 173-179.
114. Torti, C.; Quiros-Roldan, E.; Monno, L.; Patroni, A.; Saracino, A.; Angarano, G.; Tinelli, C.; Mazzotta, F.; Lo Caputo, S.; Pierotti, P.; Carosi, G. HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations. J. Acquir. Immune Defic. Syndr. 2004, 36, 1104-1107.